Insulet stock holds after Q2 beat and a cut to 2026 revenue
Published on 08/29/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Insulet stock is absorbing a sharp Q2 2026 split between stronger near-term execution and a softer full-year outlook. The company reported $801.7 million in revenue for the quarter ended August 5, 2026, alongside $1.66 EPS versus a $1.47 consensus estimate, while the stock's market cap stands at $10.06 billion as of August 29, 2026.
The current debate is the size of the revenue reset. Management set FY 2026 guidance at 6.460- EPS, and the latest consensus in market coverage points to $6.51 for the year, which leaves the company guiding below Wall Street's current view.
Q2 still beat estimates
The quarter itself was stronger than expected. Revenue of $801.7 million topped the $787.39 million estimate, and earnings improved from $1.17 a year earlier to $1.66 in Q2 2026.
That year-over-year rise of $0.49 per share matters because it shows earnings leverage even as guidance tightened. Revenue also increased 23.5% from the prior-year quarter, a pace that keeps Insulet among the faster-growing names in medical devices.
Guidance now leads the story
The market is likely to keep focusing on the gap between the quarter and the outlook. A year-ahead estimate of $6.51 per share sits just above management's FY 2026 view of 6.460- EPS, so the stock is trading against expectations that are still being revised after the report.
Market data also puts the shares in a wider frame: the 52-week range runs from $126.40 to $354.88, and the current valuation is far from the stock's upper end. That range helps explain why even an earnings beat can coexist with a cautious price response.
Omnipod stays central
Omnipod remains the company's core business and the product investors track most closely. It is the insulin delivery platform that sits behind Insulet's growth profile and the revenue base discussed in the latest quarter.
What the stock says now
Insulet trades on Nasdaq under PODD, with a market cap of $10.06 billion as of August 29, 2026. The combination of $801.7 million in quarterly revenue, $1.66 EPS, and a FY 2026 outlook of 6.460- EPS leaves the stock focused on execution, not just the beat.
Fact box
Company: Insulet Corporation
ISIN: US45784P1012
Ticker: PODD
Exchange: Nasdaq
Price (as of August 29, 2026): not supported in this call
Market cap: $10.06 billion (as of August 29, 2026)
Sector / Industry: Health Care / Medical Devices
Index membership: Nasdaq-100
More on Insulet stock
The company builds insulin delivery systems for people with diabetes, led by the Omnipod platform. That product line is the main commercial engine behind the quarter's $801.7 million in revenue.
